EP Wealth Advisors LLC Has $210,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

EP Wealth Advisors LLC reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 17.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,944 shares of the medical equipment provider’s stock after selling 414 shares during the period. EP Wealth Advisors LLC’s holdings in Zimmer Biomet were worth $210,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. Assenagon Asset Management S.A. grew its position in Zimmer Biomet by 3.5% during the second quarter. Assenagon Asset Management S.A. now owns 24,286 shares of the medical equipment provider’s stock worth $2,636,000 after buying an additional 815 shares in the last quarter. Raymond James & Associates lifted its stake in Zimmer Biomet by 4.9% during the second quarter. Raymond James & Associates now owns 108,105 shares of the medical equipment provider’s stock worth $11,733,000 after purchasing an additional 5,039 shares during the period. Dakota Wealth Management grew its stake in shares of Zimmer Biomet by 32.7% in the 2nd quarter. Dakota Wealth Management now owns 9,414 shares of the medical equipment provider’s stock valued at $1,022,000 after purchasing an additional 2,321 shares during the period. Atria Wealth Solutions Inc. boosted its stake in Zimmer Biomet by 4.0% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 16,063 shares of the medical equipment provider’s stock valued at $1,746,000 after buying an additional 617 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC bought a new position in shares of Zimmer Biomet during the second quarter valued at $283,000. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ZBH. TD Cowen dropped their target price on shares of Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a research report on Friday, September 6th. JPMorgan Chase & Co. reduced their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday, September 16th. BTIG Research dropped their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a report on Thursday, October 3rd. Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Finally, Truist Financial raised their target price on Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a research note on Friday, November 1st. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $122.83.

Zimmer Biomet Stock Down 0.1 %

Shares of Zimmer Biomet stock opened at $106.74 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90. The business has a fifty day simple moving average of $107.69 and a 200 day simple moving average of $108.70. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. The stock has a market cap of $21.25 billion, a PE ratio of 20.29, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the prior year, the business posted $1.65 EPS. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.